Date: 0000-00-00
Type of information: Series A financing round
Company: Inthera Bioscience (Switzerland)
Investors: Merck Ventures (Germany) Aglaia BioMedical Ventures (The Netherlands) Novo Seeds (Denmark)
Amount: CHF 10.5 Million (€ 9.64 million)
Funding type: series A financing round
Planned used: Inthera Bioscience is a Swiss biopharmaceutical company developing novel first-in-class oral agents blocking aberrant cell signaling in solid tumors, which are currently in pre-clinical development. The company employs a proprietary technology platform to rationally design small molecule inhibitors of intracellular protein-protein interactions (PPIs).
Others: • On May 31, 2017, Inthera Bioscience announced the closing of a Series A financing of CHF 10.5 million (€ 9.6 million). The financing round was led by Merck Ventures, with equal contribution from Aglaia BioMedical Ventures and Novo Seeds and the participation of a private investor. In conjunction with the financing round, Emmanuelle Coutanceau of Novo Seeds and Keno Gutierrez of Merck Ventures have joined the company’s Board of Directors. Earlier this year, the Board of Directors had already been strengthened with two experienced biotech executives, Klaus Schollmeier, who has assumed the Chairman role, and Anker Lundemose, joining as independent member.
Therapeutic area: Cancer - Oncology
